Cargando…
Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to deter...
Autores principales: | Coriat, Romain, Gouya, Hervé, Mir, Olivier, Ropert, Stanislas, Vignaux, Olivier, Chaussade, Stanislas, Sogni, Philippe, Pol, Stanislas, Blanchet, Benoit, Legmann, Paul, Goldwasser, François |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038868/ https://www.ncbi.nlm.nih.gov/pubmed/21340026 http://dx.doi.org/10.1371/journal.pone.0016978 |
Ejemplares similares
-
Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
por: Mir, Olivier, et al.
Publicado: (2012) -
Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study
por: Coriat, Romain, et al.
Publicado: (2016) -
Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients
por: Dréanic, Johann, et al.
Publicado: (2015) -
Impact of Obliterative Portal Venopathy Associated With Human Immunodeficiency Virus
por: Hollande, Clémence, et al.
Publicado: (2016) -
Results of the national organised colorectal cancer screening program with FIT in Paris
por: Pellat, Anna, et al.
Publicado: (2018)